Consensus classification of challenging cases of pediatric ITP reached by ICON
| Consensus classification of challenging pediatric ITP . |
|---|
| Refractory to emergent therapy is defined as no platelet response after treatment with all eligible∗ emergent pharmacotherapies. |
| Current emergent therapies: corticosteroids, IVIG, anti-D immune globulin |
| Assuming medications administered at effective dose and for adequate duration |
| Pediatric patients with ITP who are platelet nonresponsive and/or continue to demonstrate high disease burden despite treatment with multiple classes of disease-modifying therapies (≥2 mechanisms of action) represent a challenging subset of ITP. They are at higher risk of ongoing disease burden and poor response to additional therapies. They merit additional investigation to identify alternative etiologies of both immune and non-ITP, and they warrant consideration for clinical trials or novel therapies. |
| Requires documentation of all ITP medications trialed |
| Assuming medications administered at effective dose and for adequate duration |
| Definition of response is pending publication of the updated IWG definitions of platelet and symptom response |
| Consensus classification of challenging pediatric ITP . |
|---|
| Refractory to emergent therapy is defined as no platelet response after treatment with all eligible∗ emergent pharmacotherapies. |
| Current emergent therapies: corticosteroids, IVIG, anti-D immune globulin |
| Assuming medications administered at effective dose and for adequate duration |
| Pediatric patients with ITP who are platelet nonresponsive and/or continue to demonstrate high disease burden despite treatment with multiple classes of disease-modifying therapies (≥2 mechanisms of action) represent a challenging subset of ITP. They are at higher risk of ongoing disease burden and poor response to additional therapies. They merit additional investigation to identify alternative etiologies of both immune and non-ITP, and they warrant consideration for clinical trials or novel therapies. |
| Requires documentation of all ITP medications trialed |
| Assuming medications administered at effective dose and for adequate duration |
| Definition of response is pending publication of the updated IWG definitions of platelet and symptom response |
All eligible emergent pharmacotherapies include all drugs available in the patient’s institution.